Skip to main content

Advertisement

SpringerLink
Log in

Low dosage of apatinib monotherapy as rescue treatment in advanced lung squamous cell carcinoma

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Platinum-based doublet chemotherapy and radiotherapy are the standard treatment option in advanced squamous cell carcinoma patients. However, few agents could be selected for subsequent post-second-line treatment. As a small molecule inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase, apatinib had been proved in advanced gastric cancer. Here, we showed its efficacy and safety in lung squamous cell carcinoma.

Methods

In this retrospective study, 13 advanced lung squamous cell carcinoma patients were enrolled. They received doublet chemotherapy or docetaxel as the first-line treatment. After disease progressed, all patients were administrated apatinib monotherapy (250–425 mg/day) for second-line or fourth-line therapy.

Results

After apatinib monotherapy, two patients achieved partial response, four patients achieved stable disease, and seven patients achieved progression disease. The medium PFS was 3.1 months. The median OS had not yet been reached. The objective remission rate was 15.4% (2/13). The total disease control rate was 46.2% (6/13). The main advert effects were vomiting and hypertension.

Conclusion

Apatinib might be an option as rescue treatment in advanced lung squamous cell carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Gridelli C, de Marinis F, Cappuzzo F et al (2014) Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology. Clin Lung Cancer 15:173–181

    Article  PubMed  CAS  Google Scholar 

  2. Janku F, Garrido-Laguna I, Petruzelka LB et al (2011) Novel therapeutic targets in non-small cell lung cancer. J Thorac Oncol 6:1601–1612

    Article  PubMed  Google Scholar 

  3. Herbst RS, Onn A, Sandler A (2005) Angiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol 23:3243–3256

    Article  PubMed  CAS  Google Scholar 

  4. Goel HL, Mercurio AM (2013) VEGF targets the tumour cell. Nat Rev Cancer 13:871–882

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. Sandler A, Gray R, Perry MC et al (2006) Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–2550

    Article  PubMed  CAS  Google Scholar 

  6. Garon EB, Ciuleanu TE, Arrieta O et al (2014) Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384:665–673

    Article  PubMed  CAS  Google Scholar 

  7. de Gramont A, Van Cutsem E, Schmoll HJ et al (2012) Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol 13:1225–1233

    Article  PubMed  CAS  Google Scholar 

  8. Pujade-Lauraine E, Hilpert F, Weber B et al (2014) Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol 32:1302–1308

    Article  PubMed  CAS  Google Scholar 

  9. Hu X, Zhang J, Xu B et al (2014) Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer. Int J Cancer 135:1961–1969

    Article  PubMed  CAS  Google Scholar 

  10. Li J, Qin S, Xu J et al (2013) Apatinib for chemotherapy-refractory advanced metastatic gastriccancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol 31:3219–3225

    Article  PubMed  CAS  Google Scholar 

  11. Ding L, Li QJ, You KY et al (2016) The use of apatinib in treating nonsmall-cell lung cancer: case report and review of literature. Medicine (Baltimore) 95:e3598

    Article  CAS  Google Scholar 

  12. Song Z, Yu X, Lou G et al (2017) Salvage treatment with apatinib for advanced non-small-cell lung cancer. Onco Targets Ther 10:1821–1825

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. Xu J, Liu X, Yang S et al (2018) Clinical response to apatinib monotherapy in advanced non-small cell lung cancer. Asia Pac J Clin Oncol 14:264–269

    Article  PubMed  Google Scholar 

  14. Zeng DX, Wang CG, Lei W et al (2017) Efficiency of low dosage apatinib in post-first-line treatment of advanced lung adenocarcinoma. Oncotarget 8:66248–66253

    PubMed  PubMed Central  Google Scholar 

  15. Zeng DX, Wang CG, Huang JA et al (2017) Apatinib in the treatment of advanced lung adenocarcinoma with KRAS mutation. Onco Targets Ther 10:4269–4272

    Article  PubMed  PubMed Central  Google Scholar 

  16. Fang SC, Zhang HT, Zhang YM et al (2017) Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma. Onco Targets Ther 10:447–452

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  17. Mi YJ, Liang YJ, Huang HB et al (2010) Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. Cancer Res 70:7981–7991

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Funding

This study was supported by Jiangsu Province Special Program of Medical Science (BE2016672), Program of Key Talents of Medical Science in Jiangsu Province (QNRC2016745), Clinical Key Speciality Project of China, Clinical Medicine Center of Suzhou (No. SZZX201502), Suzhou Key Laboratory for Respiratory Medicine (No. SZS201617).

Author information

Author notes

  1. Da-xiong Zeng and Wei Lei contributed equally.

Authors and Affiliations

  1. Department of Respiratory and Critical Care, The First Affiliated Hospital of Soochow University, No.899, Pinghai Road, Suzhou, 215006, People’s Republic of China

    Da-xiong Zeng, Wei Lei, Chang-guo Wang, Jian-an Huang & Jun-hong Jiang

Authors
  1. Da-xiong Zeng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wei Lei
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chang-guo Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jian-an Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jun-hong Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jun-hong Jiang.

Ethics declarations

Conflict of interest

No conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zeng, Dx., Lei, W., Wang, Cg. et al. Low dosage of apatinib monotherapy as rescue treatment in advanced lung squamous cell carcinoma. Cancer Chemother Pharmacol 83, 439–442 (2019). https://doi.org/10.1007/s00280-018-3743-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-018-3743-0

Keywords

Search

Navigation